OTLK – outlook therapeutics, inc. (US:NASDAQ)

News

Outlook Therapeutics® Reports Financial Results for Fiscal Year 2024 and Provides Corporate Update
Outlook Therapeutics® Streamlines Operations
Outlook Therapeutics® Announces NICE Recommendation of LYTENAVA™ (bevacizumab gamma) for the Treatment of Wet AMD [Yahoo! Finance]
Outlook Therapeutics® Announces NICE Recommendation of LYTENAVA™ (bevacizumab gamma) for the Treatment of Wet AMD
Outlook Therapeutics® Announces Executive Leadership Transition [Yahoo! Finance]
Show more
Live Event: Join our next subscriber-only event: "The Data Driven Investor"
Register for our next upcoming LIVE training session, which will be hosted on Tuesday April 24th at 08:00 PM EST (New York Time).
Get your questions answered during the Q & A session.
For any support questions, contact our team: support@newsquantified.com